We describe five infants with severe hypotonia, feeding difficulties and varying degrees of respiratory distress. The diagnosis of PWS was initially not clinically apparent therefore they underwent neurophysiological assessment, including stimulated single fibre EMG (SSFEMG) of orbicularis oculi. SSFEMG was considered abnormal if the grand average of the mean consecutive difference (MCD), of the intervals between the stimulus and the potential (the jitter), was greater than 26 ls, or if more than 10% of the individual measurements were greater than 34 ls. All five infants showed significant abnormalities in SSFEMG, suggestive of a neuromuscular transmission disorder. Jitter measurements ranged from 34.6 to 68.7. One infant was initially diagnosed with congenital myasthenic syndrome and responded well to treatment with pyridostigmine. Cytogenetic studies subsequently confirmed the diagnosis of PWS in all five cases. This is the first report of abnormal SSFEMG findings in infants with PWS. We suggest that these infants may have an abnormality in neuromuscular junction transmission contributing to their early hypotonia and inactivity, which improves with maturation. PWS should therefore be considered in the differential diagnosis of hypotonic infants with neuromuscular junction abnormalities diagnosed by SSFEMG. Guillain-Barre syndrome (GBS), Miller Fisher syndrome (MFS) and Bickerstaff's brainstem encephalitis (BBE) are immune-mediated disorders with overlapping clinical features, whereby anti-GQ1b IgG antibody is detected in variable frequencies. In vitro studies of MFS have demonstrated anti-GQ1b IgG antibody-mediated presynaptic damage at the neuromuscular junction. Previous studies have provided electrophysiological evidence of presynaptic neuromuscular transmission defect in anti-GQ1b positive MFS patients, which persisted up to 3 months from initial presentation. In this study, we compared incremental responses antibody-positive MFS and BBE (Group 1) with antibody-negative GBS and MFS variants (Group 2) using repetitive nerve stimulation (RNS) as an electrophysiological measurement of presynaptic neuromuscular transmission defect. With 20 Hz RNS, Group 1 showed significantly greater incremental responses compared to Group 2 (t-test, p = 0.0006). With 50 Hz RNS, Group 1 also showed significantly greater incremental responses compared to Group 2 (t-test, p = 0.002). Repeat studies at 6 months demonstrated return of increments to within normal limits in all three patients in Group 1. There was significant correlation of the initial increments (mean of 20 Hz and 50 Hz) and anti-GQ1b IgG antibody titer (Pearson's correlation coefficient r = 0.76, p = 0.011). In addition to MFS, we have also shown that presynaptic dysfunction can occur in BBE. To this end, incremental responses in upper limb muscles may serve as surrogate markers for NM transmission defect in these disorders. As immunotherapy is the mainstay of treatment in these conditions, our findings of presynaptic neuromuscular transmission defect may serve as a potential parameter in selecting patients for future therapeutic trials. Antisense oligonucleotide (AON) therapy has been shown to be an effective treatment for restoring dystrophin expression in mdx mice and Duchenne muscular dystrophy (DMD) patients with out-of-frame mutations. However, to date, limited exon skipping studies have been conducted in DMD patients with large out-of-frame duplication mutations. Whilst exon-skipping one or two exons is a highly efficient process in cell culture, efficiency falls when targeting multiple exons, thus producing little of the desired end product. Therefore, we sought to understand the expression and function of large DMD duplication proteins when only two exons are removed in order to restore the reading frame. We constructed large "in-frame" DMD duplication mutation plasmids and evaluated their expression in vivo. Two out-of-frame DMD duplication mutations (dup ex22-29 and dup ex18-30) were modified to express in-frame human dystrophin transcripts (del ex21-22 dup ex23-29 and del ex17-18 dup ex19-30). In addition, an original "inframe" DMD duplication mutation (dup ex3-25) was cloned to determine if over expression of the duplicated transcript would result in protein expression. Plasmids were electroporated into TA muscles of mdx mice, and human dystrophin expression was evaluated 7 days later. Human dystrophin expression was detected at the sarcolemma for all the constructs, confirming the duplicated proteins were stable. In addition, all three proteins recruited the nNOs protein. Whilst this study indicates DMD patients with out-of-frame duplication mutations may be suitable candidates for AON therapy, further work to analyse the protective potential of restored in-frame duplication mutations is necessary. We are currently investigating DMD duplication protein function through the exclusion of Evans blue dye post treadmill exercises. In addition, plasmids will be administrated into neonatal mdx mice to assess the ability of the constructs to prevent muscle fibre degeneration. Nonsense mutations within exon 1 of DMD do not result in severe DMD but instead lead to very mild BMD, due to an alternative initiation of translation at AUG codons within in exon 6. This leads to translation of a nearly full-length but N-terminal truncated dystrophin lacking the first half of the canonical actin binding domain 1 (ABD1). We have identified the motif encoded in exon 5 that recruits ribosomes for alternate translational initiation within exon 6, and using a dual luciferase reporter system we have determined that this motif is selectively activated in muscle cell lines but not fibroblasts or HEK cells. Our data suggest that this motif is an IRES (internal ribosome entry site) as complementary experiments have ruled out any promoter activity or aberrant splicing. The exceedingly Abstracts / Neuromuscular Disorders 22 (2012) 804-908 857
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Antisense oligonucleotides-mediated exon skipping to restore dystrophin expression for DMD therapy is promising in human clinical trials. Current AON design methods are semi-empirical involving either trialand-error and/or preliminary experimentations. To increase the productivity of developing efficient AONs, a rational AON design approach is desirable. While pioneering retrospective studies have extracted many AON design variables, they were not tested prospectively to design AONs for skipping DMD exons. Here, we proposed a recipe for the design of efficient AONs that is based on the biophysical and biochemical mechanisms involved in the exon splicing process. The recipe was applied to design 23 novel AONs, each to skip one of nine DMD exons, and their exon skipping efficiencies were subsequently validated in wet experiments. 19 AONs were found to be efficacious in inducing specific exon skipping (83% of total), of which 14 were considered efficient (61% of total), i.e. induced exon skipping in >25% of total transcripts. The validated design variables facilitate the rational design of AONs that could expedite development of optimal AONs for therapy. Antisense oligomer (AO) induced dual dystrophin exon skipping was studied in the B6Ros.Cg-Dmd mdx-4Cv /J (4
